Skip to main content

Table 1 Characters for non-cancer participants in nine placebo-controlled and standard care-controlled statin trials

From: Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis

Study Year Number of participants Type Mean follow-up (years) Age (years) Statin Jadad Score
HPS 2011 20536 At increased risk of vascular events 16.3 40–80 simvastatin 40 mg 5
AURORA 2009 2773 With maintenance hemodialysis 3.2 50–80 rosuvastatin 10 mg 5
CARDS 2008 2838 With type 2 diabetes and no history of coronary heart disease (CHD) 3.9 40–75 atorvastatin 10 mg 4
JUPITER 2008 17802 Healthy 1.9 50 years and older rosuvastatin 20 mg 6
GDDS 2005 1255 With type 2 diabetes receiving maintenance hemodialysis 4 18–80 atorvastatin 20 mg 7
ALLIANCE 2004 2442 CHD patients with hyperlipidemia 4.3 61.1(atorvastotin)/61.3(usual-care) a maximum atorvastatin dose of 80 mg/day 3
PROSPER 2002 5804 With a history of, or risk factors for, vascular disease 3.2 70–82 pravastatin 40 mg 6
LIPS 2002 1677 After successful first percutaneous
coronary intervention (PCI)
3.9 18–80 fluvastatin 80 mg 6
4S 1994 4444 With CHD 5.4 35–70 simvastatin 20 mg 5